Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of the Efficacy and Safety of Linezolid by Meta-analysis for Multidrug-resistant Tuberculosis Patients

다제내성결핵 환자에서 메타분석을 통한 Linezolid의 효능 및 안전성 평가

  • Woojin Jung (College of Pharmacy, Chungnam National University) ;
  • Taewook Sung (College of Pharmacy, Chungnam National University) ;
  • Ae Jin Kim (College of Pharmacy, Chungnam National University) ;
  • Jung-woo Chae (College of Pharmacy, Chungnam National University) ;
  • Hwi-yeol Yun (College of Pharmacy, Chungnam National University)
  • Received : 2023.10.12
  • Accepted : 2023.12.19
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Linezolid has been widely used in the treatment for multidrug-resistant tuberculosis. However, there are limitations to use it such as long treatment, because of related side effects, even adequate treatment period has been needed for remission of multidrug-resistant tuberculosis (MDR-TB). Method: The meta-analysis was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. To choose literatures, systematic literature reviews were conducted with databases of PubMed, Web of Science, and EMBASE. Results: Efficacy and safety of Linezolid were determined by 85% (95% CI=79~89%, p<0.05) in the sputum culture conversion and 55% (95% CI=45~64%, p<0.01) in side effects related to linezolid, respectively. In addition, I2 was estimated by 72%. In the subgroup analysis, efficacy and safety by dose and region were analyzed. In the subgroup analysis, compared with the linezolid dose in groups greater than 600 mg/day and less than 600 mg/day, this study showed 85% (95% CI 79~90%, p>0.05) in 206 patients and 82% (95% CI 73~89%, p<0.05) in 297 patients, respectively. Also, in the subgroup analysis, adverse effects caused by linezolid occurred more than 50% of treated patients. Conclusion: Therapeutic efficacy of linezolid for MDR-TB patients was confirmed regardless of the initial dose of linezolid, especially for sputum culture conversion and it was recommended that the dose of linezolid has been more effective below 600 mg/day. However, it should be necessary to closely monitored for safety issues since serious side effects possibly occurred by administration of long period treatment.

Keywords

Acknowledgement

이 연구는 충남대학교 학술연구비, 2022년도 정부(과학기술정보통신부) 재원 정보통신기획평가원(No.RS-2022-00155857, 인공지능융합혁신인재양성사업 ( 충남대학교 )), 한국연구재단(No. NRF-2022R1A5A7085156, NRF-2022R1A2C1010929과 RS-2023-00278597)에 의해 지원을 받아 수행된 연구임.

References

  1. World Health Organization. Global Tuberculosis Report 2022 (ISBN 978-92-4-006173-6) Available from https://www.who.int/publications/i/item/9789240061729 Accessed December 20, 2023. 
  2. Surendra K, Mohan A. Multidrug-resistant tuberculosis:a menace that threatens to destabilize tuberculosis control. Chest 2006;130(1):261-72.  https://doi.org/10.1016/S0012-3692(15)50981-1
  3. Yang JS, Kim KJ, Choi H, et al. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance related gene mutations in multidrug-resistant and extensively drug-resistant. tuberculosis in Korea. Ann. Lab. Med. 2018;38(6):563-8.  https://doi.org/10.3343/alm.2018.38.6.563
  4. Zong Z, Jing W, Shi J, et al. Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant mycobacterium tuberculosis in China. Antimicrob Agents Chemother 2018;62(8):e00165-18.  https://doi.org/10.1128/AAC.00165-18
  5. Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a French cohort. Clin. Infect. Dis. 2015;60(2):188-94.  https://doi.org/10.1093/cid/ciu786
  6. Rey-Jurado E, Tudo G, de la Bellacasa JP, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int. J. Antimicrob. Agents 2013;41(3):278-80.  https://doi.org/10.1016/j.ijantimicag.2012.11.011
  7. Eker B, Ortmann J, Migliori GB, et al. Multidrug-and extensively drug-resistant tuberculosis, Germany. Emerg. Infect. Dis. 2008;14(11):1700-6.  https://doi.org/10.3201/eid1411.080729
  8. World Health Organization. WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease Available from https://www.who.int/publications/i/item/9789240022676 Accessed December 20, 2023. 
  9. Alcala L, Ruiz-Serrano MJ, Turegano CP, et al. In vitro activities of linezolid against clinical isolates of mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003;47(1):416-7.  https://doi.org/10.1128/AAC.47.1.416-417.2003
  10. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2008;178(11):1180-5.  https://doi.org/10.1164/rccm.200806-892OC
  11. Strydom N, Gupta SV, Fox WS, et al. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019;16(4):e1002773.  https://doi.org/10.1371/journal.pmed.1002773
  12. Tsona A, Metallidis S, Foroglou N, et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J. Chemother. 2010;22(1):17-9.  https://doi.org/10.1179/joc.2010.22.1.17
  13. Thirot H, Briquet C, Frippiat F, et al. Clinical use and adverse drug reaction of linezolid: a retrospective study in four Belgian hospital centers, Antibiotics (Basel). 2021;10(5):530.  https://doi.org/10.3390/antibiotics10050530
  14. Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2010;65(4):775-83.  https://doi.org/10.1093/jac/dkq017
  15. Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008;134(1):187-92.  https://doi.org/10.1378/chest.07-1988
  16. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2005;56(1):180-5.  https://doi.org/10.1093/jac/dki148
  17. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of dailyhalf dose linezolid in patients with intractable multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2006;58(3):701-4.  https://doi.org/10.1093/jac/dkl298
  18. Lee CM. The short-term therapeutic effect of Linezolid in the patients with multi-drug resistant pulmonary tuberculosis. Mokpo National Hospital 2012:40-59. 
  19. Roongruangpitayakul C, Chuchottaworn C. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand. In J Med Assoc Thai 2013;96(10):1273-82. 
  20. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clinical Infectious Diseases 2010;50(1):49-55.  https://doi.org/10.1086/648675
  21. Liu Y, Bao P, Wang D, et al. Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study. Japanese Journal of Infectious Diseases 2015;68(3):244-7.  https://doi.org/10.7883/yoken.JJID.2014.222
  22. Lifan Z, Sainan B, Feng S, et al. Linezolid for the treatment of extensively drug-resistant tuberculosis: A systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease 2019;23(12):1293-307.  https://doi.org/10.5588/ijtld.18.0822
  23. Lorenzo SD, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. In European Respiratory Journal 2012;39:770-72.  https://doi.org/10.1183/09031936.00116011
  24. Dayyab F, Iliyasu G, Ahmad B, et al. Early safety and efficacy of linezolid-based combination therapy among patients with drug-resistant tuberculosis in North-western Nigeria. International Journal of Mycobacteriology 2021;10(2):129-35.  https://doi.org/10.4103/ijmy.ijmy_57_21
  25. Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials 2016;15(1):1-17.  https://doi.org/10.1186/s12941-016-0156-y
  26. O'Meara P, Guenette JA, Raghavan N, et al. Mechanisms of dyspnea relief following radiation treatment in a patient with severe COPD. In European Respiratory Journal 2011;38:728-30.  https://doi.org/10.1183/09031936.00029411
  27. Xu HB, Jiang RH, Li L, et al. Linezolid in the treatment of MDR-TB: a retrospective clinical study. International Journal of Tuberculosis and Lung Disease 2012; 16(3):358-63.  https://doi.org/10.5588/ijtld.11.0493
  28. Abbate E, Vescovo M, Natiello M, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. Journal of Antimicrobial Chemotherapy 2012;67(2):473-7.  https://doi.org/10.1093/jac/dkr500
  29. Yi L, Yoshiyama T, Okumura M, et al. Linezolid as a potentially effective drug for the treatment of multidrug-resistant tuberculosis in Japan. Japanese Journal of Infectious Diseases 2017;70(1):96-9.  https://doi.org/10.7883/yoken.JJID.2015.629
  30. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2009;64(2):388-91.  https://doi.org/10.1093/jac/dkp171
  31. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal 2008;34(2):387-93.  https://doi.org/10.1183/09031936.00009509
  32. Nam HS, Koh WJ, Kwon OJ, et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. In International Journal of Antimicrobial Agents 2009;33(1):92-3.  https://doi.org/10.1016/j.ijantimicag.2008.06.014
  33. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis - a report of ten cases. Journal of Infection 2006;52(2):92-6.  https://doi.org/10.1016/j.jinf.2005.04.007
  34. Zhang L, Pang Y, Yu X, et al. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection 2014;42(4):705-11.  https://doi.org/10.1007/s15010-014-0632-2
  35. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. In European Respiratory Journal 2014;45(1):161-70.  https://doi.org/10.1183/09031936.00035114
  36. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. New England Journal of Medicine 2012;367(16):1508-18.  https://doi.org/10.1056/NEJMoa1201964
  37. Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. European Respiratory Journal 2012;39(4):956-62.  https://doi.org/10.1183/09031936.00076811
  38. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. In European Respiratory Journal 2011;38:730-3.  https://doi.org/10.1183/09031936.00195210
  39. Tang S, Zhang Q, Yu J, et al. Extensively drug-resistant tuberculosis, China. In Emerging Infectious Diseases 2011;17(3):558-60.  https://doi.org/10.3201/eid1703.100919
  40. Tse-Chang A, Kunimoto D, Der E, et al. Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: a retrospective case review. Can J Infect Dis Med Microbiol. 2013;24(3):e50-2.  https://doi.org/10.1155/2013/535616
  41. Koh WJ, Kwon OJ, Gwak HS et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2009;64:388-91.  https://doi.org/10.1093/jac/dkp171
  42. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR and XDR-TB: an Indian perspective. Eur Respir J. 2010;35(4):936-8. https://doi.org/10.1183/09031936.00132009